Vera Therapeutics (VERA) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $2.15B and a free-cash-flow yield of -12.6%. Nama's AI scorecard rates it Sell, 3.2 out of 10. On 12-month momentum it ranks in the middle band of its market.
AI scorecard
Sell · 3.2/10
Negative, at the mild end of Sell. As of Nov 7, 2026.
Momentum
Middle · +19.9% over 12 months ex. last
Middle fifth of its market on the past year's move.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-46.9%
How far the last close sits under the highest price of the past five years.
Market cap
$2.15B
Trailing P/E
—
Price / book
5.2
Price / sales
—
FCF yield
-12.6%
Dividend yield
—
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Revenue growth (YoY)
—
Revenue growth (3-yr annual)
—
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
1.1
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
VERA earnings
Next report: Feb 25, 2027 (Q4 2026, EPS estimate -$1.48).
Beat the EPS estimate in 2 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Nov 5, 2026
-$1.30
-$1.62
+19.8%
—
Q2 2026
Aug 10, 2026
-$1.52
-$1.59
+4.4%
$0
Q1 2026
May 7, 2026
-$1.69
-$1.37
-23.4%
$0
Q4 2025
Feb 26, 2026
-$1.39
-$1.27
-9.4%
$0
VERA analyst price target
Median target $80.50 from 14 analysts, ranging $34.00 – $100.00.
Nama's AI scorecard currently rates Vera Therapeutics Sell (3.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does VERA report earnings?
Vera Therapeutics's next scheduled report is on Feb 25, 2027. Analysts expect EPS of -$1.48.
What is the VERA price target?
The median analyst price target from 14 analysts is $80.50, with a range of $34.00 – $100.00.
Is VERA Shariah compliant?
Nama's AAOIFI-style screen reads Vera Therapeutics as Can't Tell. A figure the screen needs is missing, so it can't tell.